Outlook Therapeutics (OTLK) Gains from Investment Securities (2016 - 2026)

Outlook Therapeutics (OTLK) has reported Gains from Investment Securities for 11 consecutive years, with -$6.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 231.96% year-over-year to -$6.8 million; the TTM figure through Mar 2026 stood at -$4.7 million (up 96.38% YoY), while the FY2025 annual figure was -$43.0 million, down 11.33% from the prior year.
• Gains from Investment Securities eased to -$6.8 million in Q1 2026 per OTLK's latest filing, from $2.8 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $49.6 million in Q1 2024 and bottomed at -$59.5 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged -$5.1 million across 5 years, with a median of -$18615.0 in 2023.
• On a YoY basis, Gains from Investment Securities climbed as much as 266631.38% in 2024 and fell as far as 506136.45% in 2024.
• Outlook Therapeutics' Gains from Investment Securities stood at -$30260.0 in 2022, then surged by 276.28% to $53342.0 in 2023, then slumped by 75599.38% to -$40.3 million in 2024, then surged by 106.93% to $2.8 million in 2025, then sank by 344.93% to -$6.8 million in 2026.
• Business Quant data shows OTLK's Gains from Investment Securities at -$6.8 million in Q1 2026, $2.8 million in Q4 2025, and -$2.7 million in Q3 2025.